New treatments for patients with chronic lymphocytic leukemia
Official title: Paradigm Shift in the Management of Patients with Previously Untreated Chronic Lymphocytic Leukemia through NCI-sponsored Clinical Trials
Funded at Mayo Clinic Rochester · NIH-10942547 · Data updated 2026-11-12
This study is looking for newly diagnosed patients with chronic lymphocytic leukemia (CLL) to try out new combinations of treatments, like Venetoclax and Ibrutinib, to see how well they work, so you can get access to the latest therapies and help improve care for others in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 8, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $124,230 |
| NIH project number | 1R50CA291823-01 |
| Project ID | NIH-10942547 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients aged 65 and older who have been newly diagnosed with chronic lymphocytic leukemia.
✕Less likely to help
Patients who have previously received treatment for chronic lymphocytic leukemia may not benefit from this research.
What this research studies
This research focuses on improving the management of chronic lymphocytic leukemia (CLL) in patients, particularly those who are newly diagnosed. The approach involves conducting clinical trials to evaluate the effectiveness of combining different therapies, such as Venetoclax and Ibrutinib, in older patients. By participating in these trials, patients may receive cutting-edge treatments that are not yet widely available. The research aims to gather data on treatment outcomes and biomarkers to enhance future care for CLL patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with chronic lymphocytic leukemia, potentially improving survival rates and quality of life.
How similar studies have gone: Previous clinical trials have shown promising results with similar treatment combinations for chronic lymphocytic leukemia, indicating a potential for success in this research.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Parikh, Sameer Ashok — Mayo Clinic Rochester
- Study coordinator: Parikh, Sameer Ashok
Related research
Other NIH-funded projects on the same topics.
-
Tracing how chronic lymphocytic leukemia can change into Richter’s syndrome
A physician-scientist is studying why CLL sometimes changes into Richter’s syndrome and how this transition happens at the genetic level, with the goal of better outcomes for people living with CLL.
-
Paradigm shift in managing untreated chronic lymphocytic leukemia in older adults
A Mayo Clinic doctor is leading a national collaboration to advance new frontline treatments for older adults with chronic lymphocytic leukemia.
-
AVO: a new triplet therapy for untreated high-risk CLL
A new, time-limited combination therapy (acalabrutinib, venetoclax, and obinutuzumab) is being tested for people with newly diagnosed high-risk CLL to see how well it works and how safe it is.
-
Rewiring cancer pathways to trigger death in chronic lymphocytic leukemia
A Stanford-led study aims to use a new class of small molecules to flip cancer-driving signals so CLL cells die, offering hope for patients who have exhausted other therapies.
-
METTL3's role in driving a stubborn form of chronic lymphocytic leukemia
A cancer-related study looks at how METTL3 helps a common leukemia (CLL) grow and resist treatment, with the goal of finding better therapies.
-
Understanding why BTK inhibitors stop working in chronic lymphocytic leukemia
Researchers are studying why some people with chronic lymphocytic leukemia stop benefiting from BTK inhibitors and how to overcome that resistance.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.